ZYME · Company research
Zymeworks Inc. (ZYME): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
12records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Zymeworks (ZYME) Sets 2026 Revenue Guidance, Is The Stock Below Fair Value? - Simply Wall Street | Zymeworks (ZYME) Sets 2026 Revenue Guidance, Is The Stock Below Fair Value? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 12, 2026 | neutral | 0 | 0.6 |
| Zymeworks EVP Adam Schayowitz sells $357,557 in ZYME stock for taxes - Investing.com | Zymeworks EVP Adam Schayowitz sells $357,557 in ZYME stock for taxes Investing.com | View source ↗ | Investing.com | Oct 10, 2026 | neutral | 0 | 0.6 |
| Zymeworks (NASDAQ:ZYME) Stock: Insider Adam Schayowitz Sells 13,832 Shares - MarketBeat | Zymeworks (NASDAQ:ZYME) Stock: Insider Adam Schayowitz Sells 13,832 Shares MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| A mandatory sale covers taxes: Zymeworks (ZYME) R&D head sells 13,832 shares at $25.85. - Stock Titan | A mandatory sale covers taxes: Zymeworks (ZYME) R&D head sells 13,832 shares at $25.85. Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Officer Adam Schayowitz proposes selling 13,832 shares of Zymeworks (Nasdaq: ZYME). - Stock Titan | Officer Adam Schayowitz proposes selling 13,832 shares of Zymeworks (Nasdaq: ZYME). Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Zymeworks (NASDAQ:ZYME) Stock Price Up 4.4% - Should You Buy? - MarketBeat | Zymeworks (NASDAQ:ZYME) Stock Price Up 4.4% - Should You Buy? MarketBeat | View source ↗ | MarketBeat | Oct 7, 2026 | neutral | 0 | 0.6 |
| Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run? - Yahoo Finance | Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 28, 2026 | neutral | 0 | 0.6 |
| SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today? - Stocktwits | SJM, ZYME Stocks Hit 52-Week High – What’s Driving The Surge Today? Stocktwits | View source ↗ | Stocktwits | Aug 26, 2026 | neutral | 0 | 0.6 |
| JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy - Stocktwits | JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy Stocktwits | View source ↗ | Stocktwits | Aug 25, 2026 | neutral | 0 | 0.6 |
| Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha | Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 1, 2026 | neutral | 0 | 0.6 |
| Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run - Yahoo Finance | Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run Yahoo Finance | View source ↗ | Yahoo Finance | Jul 1, 2026 | neutral | 0 | 0.6 |
| Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? - Yahoo Finance | Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.